Arcutis Biotherapeutics, Inc. (ARQT)
28.26
+0.73
(+2.65%)
USD |
NASDAQ |
Nov 13, 16:00
28.26
0.00 (0.00%)
After-Hours: 19:59
Arcutis Biotherapeutics Net Income (Quarterly) : 8.801M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 8.801M |
| June 30, 2026 | 15.01M |
| March 31, 2026 | -11.30M |
| December 31, 2025 | 17.40M |
| September 30, 2025 | 7.41M |
| June 30, 2025 | -15.89M |
| March 31, 2025 | -25.06M |
| December 31, 2024 | -10.79M |
| September 30, 2024 | -41.54M |
| June 30, 2024 | -52.33M |
| March 31, 2024 | -35.38M |
| December 31, 2023 | -66.28M |
| September 30, 2023 | -44.76M |
| June 30, 2023 | -70.99M |
| March 31, 2023 | -80.10M |
| December 31, 2022 | -72.02M |
| September 30, 2022 | -107.71M |
| Date | Value |
|---|---|
| June 30, 2022 | -67.41M |
| March 31, 2022 | -64.32M |
| December 31, 2021 | -71.33M |
| September 30, 2021 | -56.98M |
| June 30, 2021 | -42.01M |
| March 31, 2021 | -36.04M |
| December 31, 2020 | -34.05M |
| September 30, 2020 | -38.20M |
| June 30, 2020 | -35.41M |
| March 31, 2020 | -28.01M |
| December 31, 2019 | -12.57M |
| September 30, 2019 | -14.48M |
| June 30, 2019 | -8.289M |
| March 31, 2019 | -6.658M |
| December 31, 2018 | -5.601M |
| September 30, 2018 | -7.675M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| ADMA Biologics, Inc. | 49.88M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Savara, Inc. | -42.99M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 143.92M |
| Total Expenses (Quarterly) | 135.12M |
| EPS Diluted (Quarterly) | 0.0643 |
| Enterprise Value | 3.333B |
| Gross Profit Margin (Quarterly) | 91.34% |
| Profit Margin (Quarterly) | 6.12% |
| Earnings Yield | 0.76% |
| Operating Earnings Yield | 0.93% |
| Normalized Earnings Yield | 0.7647 |